jm8b00091_si_001.pdf (479.4 kB)

Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β‑Lactamase Inhibitors and β‑Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234

Download (479.4 kB)
journal contribution
posted on 07.04.2018 by Krisztina M. Papp-Wallace, Nhu Q. Nguyen, Michael R. Jacobs, Christopher R. Bethel, Melissa D. Barnes, Vijay Kumar, Saralee Bajaksouzian, Susan D. Rudin, Philip N. Rather, Satish Bhavsar, Tadiparthi Ravikumar, Prasad K. Deshpande, Vijay Patil, Ravindra Yeole, Sachin S. Bhagwat, Mahesh V. Patel, Focco van den Akker, Robert A. Bonomo
Limited treatment options exist to combat infections caused by multidrug-resistant (MDR) Gram-negative bacteria possessing broad-spectrum β-lactamases. The design of novel β-lactamase inhibitors is of paramount importance. Here, three novel diazabicyclooctanes (DBOs), WCK 5153, zidebactam (WCK 5107), and WCK 4234 (compounds 13, respectively), were synthesized and biochemically characterized against clinically important bacteria. Compound 3 inhibited class A, C, and D β-lactamases with unprecedented k2/K values against OXA carbapenemases. Compounds 1 and 2 acylated class A and C β-lactamses rapidly but not the tested OXAs. Compounds 13 formed highly stable acyl-complexes as demonstrated by mass spectrometry. Crystallography revealed that 13 complexed with KPC-2 adopted a “chair conformation” with the sulfate occupying the carboxylate binding region. The cefepime-2 and meropenem-3 combinations were effective in murine peritonitis and neutropenic lung infection models caused by MDR Acinetobacter baumannii. Compounds 13 are novel β-lactamase inhibitors that demonstate potent cross-class inhibition, and clinical studies targeting MDR infections are warranted.